IH Quality Improvement (QI) Data Collection Tool

- This tool is intended to support data collection for the “Infantile Hemangioma CPG QI Metrics” published with the AAP IH CPG for clinicians utilizing outcome measurement as an implementation strategy.
- Questions 2-6 in this tool are also mapped to the questions in the clinical assessment tool, “IH Initial Clinical Assessment for Patients < 3mos”, published with the AAP IH CPG.

1. **Case identification**
   1.1. Patient name: ______________________
   1.2. Patient DOB: ______________________
   1.3. Date of patient’s initial IH assessment: ______________________
   1.4. Patient age at initial assessment: ______________________
   1.5. If applicable, date of initial consultation with hemangioma specialist: ______________________

2. **Is the diagnosis of IH confirmed?** *(Question 2.a.ii., IH Initial Clinical Assessment for Patients < 3mos)*
   2.1. YES: This patient is included in the denominator for APP IH CPG QI Measures, “Measure 1: Standard Assessment for Risk Stratification of Infantile Hemangioma (IH)” and “Measure 5: Parental Education After Diagnosis”
   2.2. NO: STOP. Patient is excluded from all QI measures

3. **Did this patient receive a standardized assessment for risk stratification?** *(Question 2.c.ii-vi., IH Initial Clinical Assessment for Patients < 3mos)*
   3.1. YES: This data is included in the numerator for APP IH CPG QI Measures, “Measure 1: Standard Assessment for Risk Stratification of Infantile Hemangioma (IH)”; continue to Question 4.
   3.2. NO: Continue to Question 4

4. **After initial assessment, is this patient’s IH risk “Highest”?** *(Question 2.c.iii., IH Initial Clinical Assessment for Patients < 3mos)*
   4.1. YES: Include this patient in the denominators for AAP IH CPG QI Measure 2, Hemangioma Specialist Consultation for Highest/High Risk IH AND Measure 3, Timing of Consultation for “Highest” Risk IH: Within 1 week; continue to question 4.3
   4.2. NO: Continue to question 5.
4.3. Did this patient receive consultation with a hemangioma specialist?
(Question 4.a.ii., IH Initial Clinical Assessment for Patients < 3mos)

4.3.1. YES: Include this patient in the numerator for IH CPG QI Measure 2, Hemangioma Specialist Consultation for Highest/High Risk IH; Continue to question 4.4

4.3.2. NO: Continue to question 6

4.4. Was consultation completed within 1 week of the initial assessment?
(Question 4.b.iii., IH Initial Clinical Assessment for Patients < 3mos)

4.4.1. YES: Include this patient in the numerator for IH CPG QI Measure 3, Timing of Consultation for “Highest” Risk IH: Within 1 week; Continue to question 6

4.4.2. NO: Continue to question 6

5. After initial assessment, is this patient’s IH risk “High”?
(Question 2.c.iv., IH Initial Clinical Assessment for Patients < 3mos)

5.1. YES: Include this patient in the denominator for AAP IH CPG QI Measure 2, Hemangioma Specialist Consultation for Highest/High Risk IH AND Measure 4, Timing of consultation for “High” Risk IH: Within 2 weeks; continue to question 5.3

5.2. NO: Continue to question 6

5.3. Did this patient receive consultation with a hemangioma specialist?
(Question 4.b.ii., IH Initial Clinical Assessment for Patients < 3mos)

5.3.1. YES: Include this patient in the numerator for IH CPG QI Measure 2, Hemangioma Specialist Consultation for High Risk IH; Continue to question 5.4

5.3.2. NO: Continue to question 6

5.4. Was this consultation completed within 2 weeks of the initial assessment?
(Question 4.b.iii., IH Initial Clinical Assessment for Patients < 3mos)

5.4.1. YES: Include this patient in the numerator for IH CPG QI Measure 4, Timing of Consultation for “High” Risk IH: Within 2 weeks; Continue to question 6

5.4.2. NO: Continue to question 6
6. **At the initial visit with the primary clinician/practice, did this patient’s present caregivers receive standardized information about infantile hemangioma?** *(Question 4.a-d.iv., IH Initial Clinical Assessment for Patients ≤ 3mos)*

6.1. **YES:** Include this patient in the numerator for IH CPG QI Measure 5, Parental Education After Diagnosis; Continue to question 7

6.2. **NO:** Continue to question 7

7. **Was/is this patient being treated with oral propranolol?** *(Perform chart review for visit resulting in initiation of oral propranolol treatment)*

7.1. **YES:** Include this patient in the denominator for IH CPG QI Measure 6, Parental Education For Oral Propranolol Therapy; Continue to question 7.3

7.2. **NO**

7.3. **For all encounters involving IH management AND initiation/continuation of oral propranolol therapy, did this patient’s present caregivers receive standardized education about treatment with oral propranolol?** *(Perform chart review of all visits involving management of IH AND initiation/continuation of oral propranolol therapy. “YES” means that documentation for all such visits includes evidence of standardized education consistent with the measure aim definition.)*

7.3.1. **YES:** Include this patient in the numerator for IH CPG QI Measure 6, Parental Education for Oral Propranolol Therapy

7.3.2. **NO**